153 related articles for article (PubMed ID: 33470065)
1. Peripheral blood
Jung Y; Hur S; Liu J; Lee S; Kang BS; Kim M; Choi YJ
J Gynecol Oncol; 2021 Mar; 32(2):e23. PubMed ID: 33470065
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
3. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
[TBL] [Abstract][Full Text] [Related]
7. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
8. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
10. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR; Dougherty BA; Lai Z; Fielding A; Grinsted L; Spencer S; O'Connor MJ; Ho TW; Robertson JD; Lanchbury JS; Timms KM; Gutin A; Orr M; Jones H; Gilks B; Womack C; Gourley C; Ledermann J; Barrett JC
Br J Cancer; 2018 Nov; 119(11):1401-1409. PubMed ID: 30353044
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
12. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
Cifuentes-C L; Rivera-Herrera AL; Barreto G
Colomb Med (Cali); 2019 Sep; 50(3):163-175. PubMed ID: 32284662
[TBL] [Abstract][Full Text] [Related]
15. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
[TBL] [Abstract][Full Text] [Related]
17. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
18. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
